UPB Share Price Performance
US$15.61
-6.39 (-29.05%)
Price US$15.61
Share PriceUS$15.61
UPB Community Narratives
There are no narratives available yet.
Recent UPB News & Updates
No updates
Upstream Bio, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -1.67
- Gross Margin
- 100.00%
- Net Profit Margin
- -3,904.83%
- Debt/Equity Ratio
- 0%
Upstream Bio, Inc. Competitors
About UPB
- Founded
- 2021
- Employees
- 52
- CEO
- WebsiteView website
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. Its product candidate includes verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, as well as in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
U.S. Market Performance
- 7 Days: -2.7%
- 3 Months: 11.4%
- 1 Year: 20.5%
- Year to Date: 5.9%
Over the last 7 days, the market has dropped 2.7%, driven by a decline of 2.4% in the Information Technology sector. As for the longer term, the market has actually risen by 20% in the last year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading